Pharmaceuticals (48) | Development Agreements (48)

Browse by Company

Recent Contracts

Corporate Advisory Agreement (Research & Development) between the Company and GYB, LLC dated May 18, 2021 (MJ Holdings, Inc., Filed With SEC on May 21, 2021)
Strategic Development Agreement dated March 14, 2021 (IntelGenx Technologies Corp., Filed With SEC on March 25, 2021)
Amendment to Exclusive Distribution and Licensing Agreement by and between Wize Pharma Ltd., OcuWize Ltd. and Resdevco Research and Development Company Ltd., dated May 4, 2020 (Wize Pharma, Inc., Filed With SEC on March 1, 2021)
Development and Commercialization Agreement by and between Theravance Biopharma R&D, Inc. and Mylan Ireland Limited, dated January 30, 2015 (Theravance Biopharma, Inc., Filed With SEC on February 26, 2021)
Amendment of Solicitation/Modification of Contract 00021, dated July 2, 2020, to Agreement, dated June 1, 2011 by and between SIGA and the Biomedical Advanced Research and... (SIGA TECHNOLOGIES INC, Filed With SEC on November 5, 2020)
Amendment of Solicitation/Modification of Contract 00019, dated July 20, 2020, to Agreement, dated May 13, 2011 by and between SIGA andthe Biomedical Advanced Research and... (SIGA TECHNOLOGIES INC, Filed With SEC on November 5, 2020)
Development and Manufacturing Services Agreement, dated June 10, 2015, by and between AGC Biologics A/S (formerly known as CMC Biologics A/S) and Horizon Therapeutics Ireland DAC... (Horizon Pharma plc, Filed With SEC on November 2, 2020)
Development and Supply Agreement, dated September 4, 2018 (RespireRx Pharmaceuticals Inc., Filed With SEC on October 14, 2020)
Amendment No. 1 to Research, Development and Commercialization Agreement, dated January 6, 2006 by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation... (Royalty Pharma plc, Filed With SEC on October 13, 2020)
Amendment No. 2 to Research, Development and Commercialization Agreement, dated January 1, 2006, by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation... (Royalty Pharma plc, Filed With SEC on October 13, 2020)